COMPARISON OF EFFICACY OF ITRACONAZOLE VS TERBINAFINE IN TINEA CORPORIS
Main Article Content
Keywords
Itraconazole, Terbinafine, Tinea corporis
Abstract
Background: Infection with dermatophytes is becoming more common, particularly in tropical regions. Pathogens causing Tinea showed resistant to a number of frequently used antifungals.
Aim: To compare the efficacy of terbinafine and itraconazole in the treatment of Tinea coporis infection.
Materials and Methods: This randomized parallel group trial was conducted at the department of dermatology Mian Rashid Hussain Memorial Hospital Nowshera from November 2023 to March 2024. Patients were randomly distributed into two groups based on the treatment they received. Everyone was checked on every two weeks. Results were evaluated at four and six weeks. A full clinical clearance of the lesions was deemed a cure. For each patient, the KOH positive and negative as well as fungus culturing were performed. The statistical study was conducted using the Chi-square test and parametric one-way analysis of variance (F test) using SPSS 24.
Results: With 75 individuals in each group, a total of 150 patients included in the research. Compared to 81% of patients in the itraconazole group, 60 % of patients in the terbinafine group experienced a full recovery. There was a statistically significant improvement at the six-week p value < 0.05.
Conclusion: This study showed that Itracanzole effectiveness is better than terbinafine however both can be used in Tinea corporis. Based on this study the use Itracanazole is suggested in Tinea diseases. No notable side effects were shown in both of the groups.
References
2. Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol Online J. 2016;7:77–86
3. Hay RJ, Ashbee HR. Fungal infections. In: Griffiths CE, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook’s Textbook of Dermatology. 9th ed. II. West Sussex: Wiley Blackwell; 2016. p. 945.
4. Schieke SM, Garg A. Fitzpatrick’s Dermatology in General Medicine. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ, Wolff K, editors. 8th ed. II. New York: The McGraw-Hill Companies; 2012. p. 2294.
5. Bishnoi A, Vinay K, Dogra S. Emergence of recalcitrant dermatophytosis in India. Lancet Infect Dis. 2018;18(3):250–51.
6. Garodia N, Doncker PD, Pande S, Richarz U. Itraconazole: What clinicians should know? Indian J Drugs Dermatol. 2017;3(1):4–10.
7. Panda S, Verma S. The menace of dermatophytosis in India: The evidence that we need. Indian J Dermatol, Venereol, Leprol. 2017;83(3):281–4
8. 10. Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, et al. Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18(1):6.
9. 11. Abdel-Rahman S, Newland JG. Update on terbinafine with a focus on dermatophytoses. Clin Cosmet Investig Dermatol . 2009;2:49–63.
10. 12. McClellan KJ, Wiseman LR, Markham A. Terbinafine. Drugs. 1999;58(1):179–202.
11. 13. Osborne CS, Leitner I, Favre B, Ryder NS. Amino Acid Substitution in Trichophyton rubrum Squalene Epoxidase Associated with Resistance to Terbinafine. Antimicrob Agents Chemothe. 2005;49(7):2840–4.
12. 14. Sheikh G, Majid I, Kanth F, Hakak R. Relapse after oral terbinafine therapy in dermatophytosis: A clinical and mycological study. Indian J Dermatol. 2016;61(5):529–33.
13. 15. Babu PR, Pravin AJS, Deshmukh G, Dhoot D, Samant A, Kotak B, et al. Efficacy and safety of terbinafine 500 mg once daily in patients with dermatophytosis. Indian J Dermatol. 2017;62(4):395–9.
14. 16. Shakya N, Jha S, Dangol A, Shakya S, Shah A. Efficacy of Itraconazole Versus Terbinafine for the Treatment of Tineacruris. Med J Shree Birendra Hospital. 2013;11(1):24–6.
15. 17. Chow KW, Ting HC, Yap YP, Yee KC, Purushotaman A, Subramanian S, et al. Short treatment schedules of itraconazole in dermatophytosis. Int J Dermatol. 1998;37(6):446–8.
16. 18. Rohatgi S, Ardeshna KP, Jerajani HR. Successful treatment of recurrent dermatophytosis with isotretinoin and itraconazole. Indian J Dermatol, Venereol, Leprol. 2016;82(5):579–82.
17. 21. Bhatia A, Kanish B, Badyal DK, Kate P, Choudhary S. Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin – A prospective, randomized comparative study. Indian J Pharmacol. 2019;51(2):116–9.
18. 22. Sharma P, Bhalla M, Thami GP, Chander J. Evaluation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the management of dermatophytosis. J Dermatol Treat. 2020;31(7):749– 53.
19. 23. Ellis D, Watson A. Systemic antifungal agents for cutaneous fungal infections. Aust Prescr. 1996;19(3):72–5. 24. Nozickova M, Koudelkova V, Kulikova Z, Malina L, Urbanowski S, Silny W, et al. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol. 1998;37(9):703–5.
20. 25. Rengasamy M, Chellam J, Ganapati S. Systemic therapy of dermatophytosis: Practical and systematic approach. Clin Dermatol Rev. 2017;1(3):19–23.
21. 26. Osborne CS, Leitner I, Hofbauer B, Fielding CA, Favre B, Ryder NS, et al. Biological, Biochemical, and Molecular Characterization of a New Clinical Trichophyton rubrum Isolate Resistant to Terbinafine. Aust Agents Chemother. 2006;50(6):2234–6.
22. 27. Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA, et al. Clinical Trichophyton rubrum Strain Exhibiting Primary Resistance to Terbinafine. Antimicrob Agents Chemother. 2003;47(1):82–6.
23. 28. Hosseini-Yeganeh M, McLachlan AJ. Physiologically Based Pharmacokinetic Model for Terbinafine in Rats and Humans. Antimicrob Agents Chemoth. 2002;46(7):2219–28.
24. 29. Cole GW. A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis. Arch Dermatol. 1989;125(11):1537–9.
25. 30. Hay RJ, Logan RA, Moore MK, Midgely G, Clayton YM. A comparative study of terbinafine versus griseofulvin in ‘dry-type’ dermatophyte infections. J Am Acad Dermatol. 1991;24(2):243–6.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Muhammad Sohail
MBBS, FCPS, District Specialist, Nowshera Pakistan
Shehryar Riaz
MBBS FCPS District Skin Specialist, King Abdullah Teaching Hospital, Mansehra Pakistan
Muhammad Idrees Khan
Registrar Family Medicine, Sahara Medical College, Narowal Pakistan
Fahad Faizullah
Specialist Registrar, Dermatology Department, Hayatabad Medical Complex, Peshawar Pakistan
Salman Hakim
Assistant Professor Histopathology, Sahara Medical College, Narowal Pakistan
Khalida Ikram
TMO Gynaecology Ward, Qazi Hussain Medical Complex, Nowshera Pakistan